Clinical efficacy and safety of alemtuzumab in postmarketing practice

Clinical trials confirm alemtuzumab efficacy for multiple sclerosis treatment in terms of both conventional measures and combined criteria such as NEDA (no evidence of disease activity). However, established drug efficacy and convenient dosing schedule are balanced by the risk of serious adverse events. Therefore, it is necessary to inform physicians about the benefits of alemtuzumab therapy along with the pattern of its safety profile.The present review provides the analysis of alemtuzumab real-world studies in Europe, USA and other parts of the world. The information obtained can help physicians to prescribe and administer the drug properly and to perform effective safety monitoring for early detection of adverse events and saving the maximum treatment benefit for the patient.

• Publication year

  2019

• Venue

  Medical Council

• Publication date

  2019-06-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.21518/2079-701X-2019-9-56-62
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.

  2019cited by this paper
• Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis

  2019cited by this paper
• Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.

  2018cited by this paper
• 082 Real world experience of treating multiple sclerosis with alemtuzumab

  2018cited by this paper
• Defining response profiles after alemtuzumab

  2018cited by this paper
• Editors' note: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

  2018cited by this paper
• No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

  2018cited by this paper
• Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

  2018cited by this paper
• Low rate of conversion from relapsing-remitting MS to secondary progressive MS through 6 years among patients who received alemtuzumab in CARE-MS I and II

  2017cited by this paper
• Alemtuzumab CARE-MS II 5-year follow-up

  2017cited by this paper
• Alemtuzumab CARE-MS I 5-year follow-up

  2017cited by this paper
• Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

  2017cited by this paper
• ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential

  2016cited by this paper
• Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

  2016cited by this paper
• Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

  2016cited by this paper
• Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis

  2016cited by this paper
• Clinical Outcomes of 200 Multiple Sclerosis Patients Switching from Natalizumab to Alemtuzumab in a Single United States MS Center (P3.117)

  2016cited by this paper
• Durable Efficacy of Alemtuzumab Over 10 Years: Long-Term Follow-Up of Patients with RRMS from the CAMMS223 Study (P3.053)

  2016cited by this paper
• Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).

  2016cited by this paper
• Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

  2016cited by this paper
• Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study

  2015influential reference
• Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

  2013cited by this paper
• Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

  2012cited by this paper
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

  2012cited by this paper
• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

  2012cited by this paper
• Monoclonal antibodies in MS

  2010cited by this paper
• B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

  2009cited by this paper
• Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

  2009cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis

  2005cited by this paper
• A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

  2001cited by this paper

• No citing papers are available for this paper.